TISIDB

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF00041 Fibronectin type III domain
Function	Receptor for IL27. Requires IL6ST/gp130 to mediate signal transduction in response to IL27. This signaling system acts through STAT3 and STAT1. Involved in the regulation of Th1-type immune responses. Also appears to be involved in innate defense mechanisms.

> Gene Ontology [ TOP ]
Biological Process	GO:0000018 regulation of DNA recombination GO:0001819 positive regulation of cytokine production GO:0002200 somatic diversification of immune receptors GO:0002204 somatic recombination of immunoglobulin genes involved in immune response GO:0002208 somatic diversification of immunoglobulins involved in immune response GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002312 B cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002377 immunoglobulin production GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus GO:0002637 regulation of immunoglobulin production GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002712 regulation of B cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002825 regulation of T-helper 1 type immune response GO:0002827 positive regulation of T-helper 1 type immune response GO:0002828 regulation of type 2 immune response GO:0002829 negative regulation of type 2 immune response GO:0002889 regulation of immunoglobulin mediated immune response GO:0006310 DNA recombination GO:0016064 immunoglobulin mediated immune response GO:0016444 somatic cell DNA recombination GO:0016445 somatic diversification of immunoglobulins GO:0016447 somatic recombination of immunoglobulin gene segments GO:0019724 B cell mediated immunity GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032729 positive regulation of interferon-gamma production GO:0042088 T-helper 1 type immune response GO:0042092 type 2 immune response GO:0042113 B cell activation GO:0042742 defense response to bacterium GO:0045190 isotype switching GO:0045191 regulation of isotype switching GO:0048291 isotype switching to IgG isotypes GO:0048302 regulation of isotype switching to IgG isotypes GO:0050777 negative regulation of immune response GO:0050830 defense response to Gram-positive bacterium GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0051052 regulation of DNA metabolic process GO:0051249 regulation of lymphocyte activation GO:0070106 interleukin-27-mediated signaling pathway GO:0098542 defense response to other organism
Molecular Function	GO:0004896 cytokine receptor activity GO:0030368 interleukin-17 receptor activity GO:0045509 interleukin-27 receptor activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04630 Jak-STAT signaling pathway
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-6788467: IL-6-type cytokine receptor ligand interactions R-HSA-168256: Immune System R-HSA-6783589: Interleukin-6 family signaling R-HSA-449147: Signaling by Interleukins

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IL27RA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between IL27RA and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19549909	Breast Carcinoma; Head and Neck Squamous Cell Carcinoma	Promote immunity	Expression of exogenous WSX1 in epithelial tumor cells suppresses tumorigenicity in vitro and inhibits tumor growth in vivo. Different from the role of WSX1 in immune cells, the antitumor activity of WSX1 in epithelial tumor cells is independent of IL-27 signaling but is mainly dependent on natural killer (NK) cell surveillance. Deficiency of either the IL-27 subunit EBV-induced gene 3 or the IL-27 receptor WSX1 in the host animals had no effect on tumor growth inhibition induced by WSX1 expression in tumor cells. Expression of WSX1 in epithelial tumor cells enhances NK cell cytolytic activity against tumor cells, whereas the absence of functional NK cells impairs the WSX1-mediated inhibition of epithelial tumor growth. Our results reveal an IL-27-independent function of WSX1: sensitizing NK cell-mediated antitumor surveillance via a NKG2D-dependent mechanism.

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IL27RA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IL27RA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.452	0.355
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.875	0.556
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.138	0.898
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.411	0.347
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.665	0.615
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.092	0.957
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.528	0.308
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.642	0.579
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.436	0.725
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.785	0.51
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.063	0.549
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.13	0.432

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IL27RA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	5.5	1.9	0.66
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	7.4	-7.4	0.169
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL27RA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL27RA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL27RA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL27RA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IL27RA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IL27RA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IL27RA
Name	interleukin 27 receptor, alpha
Aliases	WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IL27RA collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse IL27RA